OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx is positioned as a higher-margin healthcare technology platform rather than a legacy ad business, with 2Q26 EBITDA margin expanding to 24.1% and gross margin reaching 76.5% even as revenue fell 30% year over year. Its point-of-care network reaches more than 2 million HCPs and 240 million patients, while DAAP grew 30% year over year in 2Q26 and DeepIntent’s May 2026 integration opens a second programmatic growth engine that can better monetize underused EHR inventory. The balance sheet also improved materially, with a May 2026 refinancing at about 6.5%, $8.3 million of repayments, and a flip to a $5.1 million net cash position, supporting stronger financial flexibility and a more credible path to 2027 profitability.

OptimizeRx is facing a fundamentally fragile revenue base, as net revenue retention fell to 90% from 121% and TTM revenue per top 20 pharma manufacturer declined 14% to $2.7M, highlighting weaker expansion and reliance on a few large accounts. Customer concentration remains elevated, with three customers over 10% of 2025 revenue, 54% of TTM revenue from the top 20 pharma manufacturers, and about 62% of 2025 revenue flowing through just two channel partners, creating meaningful margin and renewal risk. Visibility is further pressured by a 13% revenue guide cut to $95M–$100M, managed-services unwind volatility, execution shortfalls at a top 3 account, and MFN and IRA policy risks that could restrain pharma marketing budgets.